Focused On-demand Library for Large ribosomal subunit protein bL33m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O75394

UPID:

RM33_HUMAN

Alternative names:

39S ribosomal protein L33, mitochondrial

Alternative UPACC:

O75394; Q53RZ6; Q5FVE3; Q96Q50

Background:

The Large ribosomal subunit protein bL33m, also known as 39S ribosomal protein L33, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is part of the machinery responsible for protein synthesis within mitochondria, reflecting its essential function in cellular energy metabolism and production. The protein's involvement in the mitochondrial ribosome highlights its importance in the translation of mitochondrial DNA-encoded proteins, which are pivotal for mitochondrial function.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein bL33m could open doors to potential therapeutic strategies. Its critical function in mitochondrial protein synthesis makes it a potential target for interventions aimed at mitochondrial diseases or disorders associated with mitochondrial dysfunction.